VDA-1275 / Vidac Pharma - LARVOL DELTA

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces that the United States Patent and Trademark Office (USPTO) has issued a patent to the company offering broad protection of the mode of action underlying its oncology and onco-dermatologic therapeutic candidates. The patent protects the use of Vidac’s new chemical entities to detach the hexokinase2 isozyme from the mitochondrial VDAC pores to reverse the hyperglycolytic metabolism of cancer cells...Vidac Pharma’s two product candidates - VDA-1275 as well as the more advanced VDA-1102 - disrupt the interaction between hexokinase 2 (HK2) and the voltage-dependent anion channels (VDACs) in mitochondria."

Patent • Cutaneous T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces that promising results of its study with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors are now available online, as a preprint submitted to peer review...The main findings of the study were that VDA-1275: reinstates apoptosis (programmed cell death), halts rapid proliferation of cancer cells, reduces the hyper-glycolytic metabolism typical of tumors, a process that produces the main fuel for the rapid proliferation of cancer cells, triggers an immunologic response by inducing anti-tumor macrophages and inhibits tumor-promoting macrophages and promoting anti-tumor memory cells, increases survival in a murine colorectal cancer model in a statistically significant way, demonstrates a synergistic effect in combination with widely used anti-cancer drugs in a 3D organoid model of human liver cancer."

Preclinical • Colorectal Cancer • Liver Cancer • Oncology • Solid Tumor

Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275."

Patent • Cutaneous T-cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate (GlobeNewswire) - "Vidac Pharma Holdings Plc...announces it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate, which has shown multiple promising effects in preclinical studies."

Patent • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids (GlobeNewswire) - "Vidac Pharma Holdings Plc...announced promising results for its drug candidate VDA-1275 in multiple mouse cancer and human cellular organoid model of solid tumors. VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments: sorafenib, a kinase inhibitor, and cisplatin, a widely used chemotherapy drug. The study also showed that VDA-1275 induced an immunologic response, inducing anti-tumor macrophages and memory T-cells, and inhibiting tumor-promoting macrophages...As a stand-alone treatment, VDA-1275 statistically significantly increased survival in a murine colorectal cancer model, with a survival benefit similar to Opdivo in a head-to-head comparison."

Preclinical • Colorectal Cancer • Solid Tumor

Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy (GlobeNewswire) - "Vidac Pharma Holdings Plc...announced results from an in vitro study of VDA-1275 in combination with chemotherapeutic agents to treat solid tumors, using a human cell culture that mimics most aspects of human tumors. In the study, VDA-1275, a potent small molecule that reverses the cancer cell hyper glycolytic metabolism (Warburg effect), showed both antiproliferative properties and an increase in cell death in multiple tumor types."

Preclinical • Oncology • Solid Tumor